Research programme: disulfide rich peptides - Protagonist Therapeutics

Drug Profile

Research programme: disulfide rich peptides - Protagonist Therapeutics

Alternative Names: Hepcidin agonists - Protagonist Therapeutics; Interleukin-23 receptor antagonist - Protagonist Therapeutics; Nav1.7 voltage gated sodium channel modulators - Protagonist Thearapeutics; PTG 200; PTG-300

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator Protagonist Therapeutics
  • Class Disulfides; Peptides
  • Mechanism of Action Alpha4-beta7 integrin antagonists; Hepcidin stimulants; Interleukin-23 receptor antagonists; Nav1.7-voltage-gated-sodium-channel-modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Beta-thalassaemia; Haemochromatosis; Neuropathic pain

Highest Development Phases

  • Preclinical Inflammatory bowel diseases; Iron overload
  • No development reported Neuropathic pain

Most Recent Events

  • 12 May 2017 No development reported - Preclinical for Neuropathic pain in USA (Parenteral)
  • 10 May 2017 Preclinical trials in Iron overload in USA (Parenteral)
  • 10 May 2017 Protagonist Therapeutics plans a phase I trial for PTG 200 for Crohn's disease in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top